Novartis considers upgrading growth outlook as drug trial data approaches

10 articles · Updated · The Wall Street Journal · Apr 28

Novartis reported first-quarter sales of $13.11 billion, a 5% decline, and core operating profit down 14% to $4.9 billion, citing generic competition.
The Swiss company reaffirmed its 2026 guidance, expecting low-single-digit sales growth and a similar decline in core operating income.
Novartis may raise its mid- to long-term growth outlook pending results from multiple drug trials in the second half of 2026, building on its 2025-30 annual growth target of 5% to 6%.

Can Novartis's drug pipeline truly outrun the 'historic' patent cliff and new US tariffs threatening its future?

With hopes pinned on a new cholesterol drug, what is Novartis's Plan B if pivotal trial data disappoints later this year?

Novartis is building a billion-dollar AI research hub. Can this massive investment deliver the next generation of blockbuster drugs?

Amid an FDA crackdown on trial secrecy, will Novartis publish all its crucial results, whether they are good or bad?

Novartis just launched a new hives drug. Can it successfully challenge established rivals in a highly competitive market?

President Trump’s new tariffs target patented drugs. How will this policy reshape the US pharmaceutical landscape for foreign companies?